|
|
BGI Genomics
Products >> BGI Genomics Sees Diagnostics Core Business Rebounding, Overseas
Build Your Online Product Catalogs?
| Product Name: |
BGI Genomics Sees Diagnostics Core Business Rebounding, Overseas
|
| Supply Ability: |
|
| Related proudcts |
|
| Specifications |
BGI Genomics Sees Diagnostics Core Business Rebounding, Overseas |
| Price Term: |
|
| Port of loading: |
|
| Minimum Order |
|
| Unit Price: |
|
|
NEW YORK ¨C BGI Genomics has seen growth in several areas of its core diagnostic testing business during the first half of 2021 and is working on upgrading its tests in reproductive health.
Late last month, the publicly traded clinical BGI gene test and research services arm of China's BGI Group reported that total revenues in H1 declined due to decreasing demand for COVID-19 testing, while its cancer prevention and control, reproductive health including its flagship NIFTY noninvasive prenatal test, and infection prevention and control businesses grew.
Li Ning, VP of BGI Group, said the regular business is "healthy" even as COVID testing demand is declining. He noted that the four biggest non-COVID drivers of revenue for the six-month period were cancer testing, infection prevention, reproductive health, and overseas growth.
The NIFTY test, which was launched in 2014 after approval from China's National Medical Products Administration, has been distributed in more than 60 countries, and more than 9.4 million tests have been performed in total, Li said. |
| Company: |
BGI Genomics
|
| Contact: |
Tommy Ru |
| Address: |
beijing |
| Postcode: |
|
| Tel: |
17722567742 |
| Fax: |
|
| E-mail: |
|
|
|
|
Home
